Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday

Contineum Therapeutics (NASDAQ:CTNM) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $5.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Contineum Therapeutics Stock Performance

Contineum Therapeutics stock opened at $15.78 on Thursday. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.33. The stock has a market cap of $460.46 million, a price-to-earnings ratio of -7.01 and a beta of 1.18. The stock’s 50 day simple moving average is $13.01 and its two-hundred day simple moving average is $11.69.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CTNM shares. Robert W. Baird dropped their price target on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, November 24th. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st. Royal Bank Of Canada lowered their price target on shares of Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a research report on Friday, November 21st. Finally, Leerink Partners initiated coverage on shares of Contineum Therapeutics in a research note on Thursday, November 13th. They set an “outperform” rating and a $22.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Hedge Funds Weigh In On Contineum Therapeutics

A number of hedge funds have recently bought and sold shares of CTNM. Strs Ohio purchased a new stake in Contineum Therapeutics during the 1st quarter valued at about $27,000. Bank of America Corp DE lifted its stake in shares of Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock worth $85,000 after buying an additional 6,030 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics during the second quarter valued at approximately $43,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Contineum Therapeutics during the fourth quarter valued at approximately $130,000. Finally, Marex Group plc purchased a new position in Contineum Therapeutics in the 2nd quarter worth approximately $45,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.